First: what actually determines pill effectiveness
David: I have a thought
Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial
Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema
Some weight regain is common: Studies show most people regain all or more of the weight within a year after stopping GLP-1 medications
The data on those features are pretty new and still pretty small, but they're enticing in the sense that this class of drugs affects a lot of the way our hypothalamus functions in terms of modulating drives and impulses, in addition to the direct anti-obesity and metabolic benefits of the drugs